ea0089t6 | Trials In Progress | NANETS2022
Hope Thomas
, Mehr Samuel
, Morris Michael
, Li Daneng
, Halperin, MD Daniel
, Strosberg Jonathan
, Soares Heloisa
, Jacene Heather
, Pavel Marianne
, L. Kunz Pamela
, Ferreira Denis
, Li Joanne
, Ma Kimberly
, Rearden Jessica
, Moran Susan
, Singh Simron
Background: Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are commonly characterized by overexpression of somatostatin receptor subtype 2 (SSTR2), which can be targeted by radiopharmaceutical therapy (RPT) via radiolabeled somatostatin analogues (SSAs). RYZ101 (Ac-225 DOTATATE) is a first-in-class, highly potent alpha-emitting RPT being developed for the treatment of SSTR2+ solid tumors. Alpha-particles (such as emitted by Actinium-225) have a sho...